Syndax Pharmaceuticals reports Q1 2026 results after market close today, entering the print with its stock down 6.6% on the week and 12% over the past month — back to prices last seen before a brief rally this spring. The tension heading in is straightforward: a high and stable short position sits alongside a Street consensus that still sees nearly 90% upside from current levels.
Short sellers have a firm grip on the stock, and there is little sign they are retreating ahead of earnings. SI as a percentage of the free float is running at 24.2% — a level that has barely moved over the past six weeks, edging up roughly 1.3% on the week and just over 2.6% over the past month. The short score from ORTEX is 69.6, just off the recent peak of 70.5 hit earlier in April. Importantly, the borrow market does not reflect a squeeze setup. Availability is generous: the lending pool remains well-stocked relative to the volume of shares already borrowed, with cost to borrow a benign 0.38% annually — down 11% on the week and at its lowest point of the past 30 days. Bears can add exposure cheaply if they choose to.
Options traders are leaning bullish, offering a partial counterweight to that short positioning. The put/call ratio is 0.30, barely above its 20-day average of 0.28 and well below the 52-week high of 0.93 hit when sentiment was far more defensive. The z-score of 0.23 signals no unusual hedging activity — options positioning, in short, is closer to relaxed than anxious. That stands in contrast to the short base, which remains elevated and sticky. When short interest is this high but options traders are not buying protection, the two camps are genuinely split on direction.
The Street is firmly in the bull camp — but has been dialling back ambition. Goldman Sachs raised its target to $34 from $28 on April 1, maintaining a Buy, and is the most recent bellwether move of note. Before that, both Mizuho and Jefferies trimmed targets at the end of March — to $43 and $40 respectively — while keeping positive ratings. JP Morgan had raised to $45 in early March. The mean consensus target now sits around $39–$40, roughly 90% above the current price of $20.63. That gap has been a persistent feature of SNDX coverage, driven by enthusiasm for revumenib's early combination data in acute leukemias — strong complete response rates and MRD-negative outcomes have been the bull thesis anchor. The bear case centres on expanded boxed-warning risk, the potential for regulatory delays, and the binary nature of clinical-stage oncology. Note: the Mizuho entry from January 2026 showing a $600 target appears to be a data anomaly and has been excluded.
Institutional ownership adds texture to the picture. Vanguard added 1.09 million shares in Q1 2026, bringing its stake to 7.1% of the company. State Street also added 743,000 shares over the same period. Those are passive-index-driven additions, but they reflect the stock's continued presence in small-cap biotech benchmarks. Insider activity, by contrast, has been muted and routine — the CEO and CFO both sold modest amounts in early February at prices around $20.60–$21.03, consistent with pre-planned selling rather than any directional signal.
Looking at earnings history: the last confirmed print in early March saw the stock fall 2.3% on the day but recover strongly to a 9% gain over the following five sessions. The February print — which included both an announcement and earnings call — produced a 4.6% gain on day one and a further 4% over the week. With the RSI sitting at 32.6, the stock is trading in oversold territory, and the EPS surprise factor score ranks in the 81st percentile — suggesting Syndax has a strong recent track record of beating estimates. What to watch today: whether revumenib's commercial ramp shows acceleration in Q1 revenues and whether management updates guidance on the frontline combination programme will determine whether the current gap between price and consensus target begins to close.
See the live data behind this article on ORTEX.
Open SNDX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
